In a subgroup of patients suffering from atopic dermatitis (AD), treatment is quite difficult even after taking oral immunosuppressants. High-dose intravenous immunoglobulin (IVIG) treatment has been reported to be beneficial for them in a few uncontrolled trials. Herein we report a case of intractable AD in a 5-year-old girl who had significant clinical improvement after receiving 3 cycles of IVIG treatment (2 g/kg) without notable side effects. Since the first infusion of IVIG, the patient's skin lesions improved steadily and the improvement persisted until the 8-month follow-up. The eczema area and severity index score decreased remarkably, while immunologic parameters did not correlate with clinical improvement. This case suggests that IVIG therapy can be quite effective and safe for children with resistant AD.
展开▼
机译：在患有特应性皮炎（AD）的患者亚组中，即使服用口服免疫抑制剂也很难治疗。在一些非对照试验中，据报道大剂量静脉内免疫球蛋白（IVIG）治疗对他们有益。在此，我们报道了一个5岁女孩的顽固性AD病例，该女孩在接受3个周期的IVIG治疗（2 g / kg）后明显改善了临床症状，而没有明显的副作用。自首次输注IVIG以来，患者的皮肤病变稳定改善，并且这种改善一直持续到8个月的随访。湿疹面积和严重程度指数显着下降，而免疫学指标与临床改善无关。该病例表明，IVIG治疗对于耐药性AD儿童可以非常有效和安全。
展开▼
